Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Effective as of June 28, 2022, the Board of Directors (the "Board") of ChemoCentryx, Inc. (the "Company") increased the size of the Board from eight to nine members, and upon the recommendation of the Nominating and Corporate Governance Committee and pursuant to the bylaws of the Company appointed Jennifer L. Herron, age 52, as an independent director. Ms. Herron was appointed to serve as a Class I director, with an initial term expiring at the 2024 annual meeting of stockholders of the Company.

Ms. Herron has served as Senior Vice President and Chief Commercial Officer of ADC Therapeutics since November 2019. Before joining ADC Therapeutics, Ms. Herron was Executive Vice President and Chief Commercial Officer at Immunogen from February 2019 to March 2019. She previously served as President and Executive Vice President, Global Commercial, at MorphoSys US from July 2018 to November 2018 and Executive Vice President and Chief Commercial Officer at Ariad Pharmaceuticals from May 2016 to April 2017. Earlier in her career, she held commercial leadership roles with Bristol-Myers Squibb, Novartis Oncology, and SmithKline Beecham Oncology (GlaxoSmithKline).

Ms. Herron holds an MBA from Georgetown University and a BA in Biology and Economics from Lehigh University.

There are no arrangements or understandings between Ms. Herron and any other persons pursuant to which she was selected as a director, and there are no related person transactions (within the meaning of Item 404(a) of Regulation S-K) between Ms. Herron and the Company.

Item 7.01. Regulation FD Disclosure

On July 5, 2022, the Company issued a press release announcing changes to the composition of its Board of Directors. Jennifer L. Herron has been appointed to the Board as an independent director effective June 28, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this report.

The information contained in this Item 7.01, including the exhibit referenced herein, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:



Exhibit
Number       Description

99.1           Press release issued by ChemoCentryx, Inc., dated July 5, 2022.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses